chufangao/CTO huggingface dataset:
Clinical trial NCT04055168: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects
Official title: A Phase I Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 After Single Dosing to Healthy Subjects
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: It was decided to not run the Japanese cohorts in the study.
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-24
Primary completion date: 2020-02-10
Completion date: 2020-02-10
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04002037: Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
Official title: Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis: A Double-Blind Prospective Randomized Clinical Trial
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Preliminary analysis revealed no difference
Enrollment: 95.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-25
Primary completion date: 2022-05-19
Completion date: 2023-01-01
Clinical trial NCT03846570: Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial
Official title: Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial
Acronym: FORZA
Sponsor: Erasmus Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Insufficient inclusion rate (due to COVID-19 pandemic)
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-29
Primary completion date: 2022-07-05
Completion date: 2022-07-05
Plan to share individual participant data: YES
IPD time frame: 36 months after publication
IPD access criteria: Data can be requested immediately following publication up to 36 months, after which the data will be filed in the Erasmus MC respiratory medicine department archives without further research support. Data requests are to be addressed to: research.longziekten@erasmusmc.nl
Clinical trial NCT04441385: Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Official title: Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Acronym: MARACOVID
Sponsor: Hospital Universitario Infanta Leonor (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of viability
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-26
Primary completion date: 2021-02-08
Completion date: 2021-02-08
Clinical trial NCT02697734: Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Official title: A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Acronym: LINC-4
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 73.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-03
Primary completion date: 2019-06-19
Completion date: 2020-12-31
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04110496: Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
Official title: A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria
Sponsor: Rubius Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The trial was discontinued by the Sponsor
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-29
Primary completion date: 2022-12-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT04162301: A Study of CS3002 in Subjects With Advanced Solid Tumors
Official title: A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activities of CS3002, a CDK4/6 Inhibitor, in Subjects With Advanced Solid Tumors
Sponsor: CStone Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study has been stopped for strategic and business reasons.
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-30
Primary completion date: 2021-02-19
Completion date: 2021-02-19
Clinical trial NCT04111497: Glasdegib for Chronic Graft-Versus-Host Disease
Official title: A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study closed to accrual early due to side effects of study drug.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-03
Primary completion date: 2023-08-23
Completion date: 2023-08-23
Plan to share individual participant data: NO
Clinical trial NCT03584516: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Official title: GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision.
Enrollment: 155.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-17
Primary completion date: 2023-11-03
Completion date: 2023-11-03
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT04106362: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
Official title: Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-14
Primary completion date: 2023-05-23
Completion date: 2023-05-23
Clinical trial NCT05727657: Satralizumab in Aneurysmal Subarachnoid Hemorrhage
Official title: A Phase 1 Clinical Trial of Satralizumab as a Treatment for Aneurysmal Subarachnoid Hemorrhage
Acronym: SASH
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Lost support from the drug manufacturer
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-06-30
Primary completion date: 2024-06-24
Completion date: 2024-06-24
Plan to share individual participant data: NO
Clinical trial NCT03781817: Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
Official title: Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Transition/change of primary investigators
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-09
Primary completion date: 2022-01-21
Completion date: 2022-04-30
Plan to share individual participant data: NO
Clinical trial NCT03502694: Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
Official title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus
Acronym: STEP
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-05
Primary completion date: 2019-04-30
Completion date: 2020-10-28
Clinical trial NCT03417245: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Official title: ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-01
Primary completion date: 2021-01-26
Completion date: 2021-07-14
Baseline population: Analysis was performed on intent-to-treat (ITT) population which included all randomized participants analyzed according to the randomized arm.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03422419: TIPS or Anticoagulation in Portal Vein Thrombosis
Official title: An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis
Acronym: PROGRESS
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-01
Primary completion date: 2020-10-31
Completion date: 2021-07-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03647423: QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Official title: QUILT-3.091 NANT Chordoma Vaccine: A Randomized Phase 1b/2 Trial of the NANT Chordoma Vaccine vs. Radiation in Subjects With Unresectable Chordoma.
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Trial not initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-31
Primary completion date: 2020-08-31
Completion date: 2022-08-30
Plan to share individual participant data: NO
Clinical trial NCT03757403: RDD1609 as a Treatment for Idiopathic Pruritus Ani
Official title: RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study
Sponsor: RDD Pharma Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Covid-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2020-11-30
Completion date: 2020-12-31
Clinical trial NCT04100590: Eye Tracking as a Biomarker of Cannabis Effects
Official title: Eye Tracking as a Biomarker of Cannabis Effects
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: During a piloting phase with our staff, the technology/eye-tracking device did not collect outcomes as expected.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-01
Primary completion date: 2019-12-30
Completion date: 2020-01-31
Plan to share individual participant data: UNDECIDED
IPD sharing description: De-identified eye-behavior data will be available to other researchers.
Clinical trial NCT03681184: A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Official title: ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Acronym: ILLUMINATE-A
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-27
Primary completion date: 2019-11-05
Completion date: 2024-01-12
Baseline population: Full Analysis Set (FAS): All randomized participants who received any amount of study drug, was used for all baseline characteristics, except for 24-hour urinary oxalate excretion corrected for body surface area (BSA), which used the Safety Analysis Set (SAS): All participants who received any amount of study drug.
Plan to share individual participant data: NO
Clinical trial NCT03317457: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Official title: A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Acronym: MEDISARC
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-15
Primary completion date: 2022-08-12
Completion date: 2022-08-12
Plan to share individual participant data: NO
Clinical trial NCT04278963: Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
Official title: Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19
Sponsor: China Academy of Chinese Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: There were no eligible patients in the paticipated centers.
Enrollment: 300.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2021-10-31
Primary completion date: 2022-12-31
Completion date: 2023-05-31
Clinical trial NCT06188104: Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test
Official title: Efficacy of Topical 95% Trichloroaceteic Acid in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test: A Randomized Controlled Trial
Sponsor: Rajavithi Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: I have found it is quite difficult to conduct the work without changing some detail in original protocol. So we would like to re-start the study again with some modification.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2023-11-30
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Clinical trial NCT05095311: The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers
Official title: The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The recruited population was no longer made available to participate in the study.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-19
Primary completion date: 2022-04-27
Completion date: 2022-04-27
Plan to share individual participant data: YES
IPD sharing description: IPD will be published in the form of a dissertation document.
IPD time frame: Data will be made available upon degree certification (anticipated May 2022) and will be available indefinitely.
IPD access criteria: The dissertation document will be publicly available.
Clinical trial NCT05027048: Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Official title: Calcium Chloride for Prevention of Blood Loss From Uterine Atony During Intrapartum Cesarean Delivery (CALBLOC): a Double Blind, Randomized, Placebo Controlled Trial and Nested Population Pharmacokinetic and Pharmacodynamic Analysis
Acronym: CALBLOC
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-04
Primary completion date: 2023-03-29
Completion date: 2023-04-03
Plan to share individual participant data: NO
Clinical trial NCT05292976: Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Official title: Multi-center, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Crossover Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg in Stable Mild Asthma Patients
Sponsor: Aurobindo Pharma Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Business reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-04-30
Primary completion date: 2022-10-31
Completion date: 2022-12-31
Clinical trial NCT03029247: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
Official title: A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-27
Primary completion date: 2020-07-09
Completion date: 2020-07-09
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT02819635: A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 1302.0 (ACTUAL)
Number of arms: 8.0
Start date: 2016-09-26
Primary completion date: 2021-12-13
Completion date: 2021-12-13
Baseline population: Intent-to-treat (ITT) analysis set: Substudy 1 (all randomized participants who received at least one dose of study drug in Substudy 1); Substudy 2 (all randomized participants who received at least one dose of doubleblinded study drug in Part 1 and all participants who received at least one dose of upadacitinib 45 mg in Part 2); Substudy 3 (all M14-675 participants who received at least one dose of study drug in Substudy 3)
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04936113: Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
Official title: An Open-Label, Multicenter Study to Evaluate Continued Safety of FB-401 for up to 48 Weeks in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in FB401-01 Phase 2 Study
Sponsor: Forte Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Failure of the Phase 2 study (protocol FB401-01) to meet its endpoint.
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-02
Primary completion date: 2021-09-30
Completion date: 2021-09-30